Related Experiment Video

Updated: May 24, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically

Kristen M Holmes1, Matti Annala, Corrine Y X Chua

  • 1Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Proceedings of the National Academy of Sciences of the United States of America
|February 21, 2012
PubMed

Insights

Insulin-like growth factor-binding protein 2 (IGFBP2) drives glioma progression by activating integrin and ILK pathways. Targeting this IGFBP2 network significantly inhibits tumor growth, offering new therapeutic strategies for glioma patients.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer genetics

Background:

  • Insulin-like growth factor-binding protein 2 (IGFBP2) is recognized as a glioma oncogene.
  • IGFBP2 presents a potential target for novel therapeutic interventions in glioma treatment.

Purpose of the Study:

  • To characterize the IGFBP2 network in glioma.
  • To investigate the role of IGFBP2 in glioma progression and identify potential therapeutic targets.

Main Methods:

  • Integrative approach combining transcriptional profiling of human glioma.
  • Validation in glial cells and a glioma mouse model.
  • Analysis of IGFBP2 interactions with integrin and integrin-linked kinase (ILK) pathways.

Main Results:

  • IGFBP2 expression correlates with genes in the integrin/ILK pathways, impacting patient prognosis.
  • IGFBP2 activates integrin β1, downstream invasion pathways, ILK-mediated cell motility, and NF-κB.
  • The IGFBP2/integrin/ILK/NF-κB network is a key in vivo pathway driving glioma progression.

Conclusions:

  • The identified IGFBP2 signaling network is crucial for glioma progression.
  • Interference with this pathway significantly inhibits glioma growth in vivo.
  • This network represents a targetable pathway for improving glioma patient survival.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...